Suppr超能文献

应对新冠疫情的科技机遇、挑战与方向

Opportunities, Challenges and Directions in Science and Technology for Tackling COVID-19.

作者信息

Podile Appa Rao, Basu Anirban

机构信息

Department of Plant Sciences, School of Life Sciences, University of Hyderabad, P.O. Central University Campus, Hyderabad, Telangana 500 046 India.

出版信息

Trans Indian Natl Acad Eng. 2020;5(2):97-101. doi: 10.1007/s41403-020-00111-z. Epub 2020 May 26.

Abstract

The ongoing global crisis due to Coronavirus disease-2019 (COVID-19) pandemic has caused an enormous socioeconomic burden. A novel coronavirus causing severe acute respiratory syndrome (SARS-CoV-2) that evolved from a virus infecting bats is responsible for COVID-19, first reported in the Chinese city of Wuhan. In the absence of any specific scientifically proven and clinically tested drug or vaccine against SARS-CoV-2, the virus is wreaking havoc across the world, claiming more than 2,50,000 lives in less than 5 months, and posed a global health emergency. The scientific community is relentlessly working on the design and testing of vaccines and antiviral drugs against the novel coronavirus, several of which have reached advanced stages of testing and are undergoing clinical trials. Here we discuss the recent advances and developments in understanding the etiology and epidemiology of the COVID-19 pandemic, the factors influencing the disease transmission, and the countermeasures adopted to combat and stop further spread of the disease.

摘要

2019年冠状病毒病(COVID-19)大流行引发的持续全球危机已造成巨大的社会经济负担。一种导致严重急性呼吸综合征的新型冠状病毒(SARS-CoV-2)由一种感染蝙蝠的病毒进化而来,它是COVID-19的病原体,该病首次在中国武汉市被报道。由于缺乏任何针对SARS-CoV-2的经过科学验证和临床测试的特效药物或疫苗,这种病毒正在全球肆虐,在不到五个月的时间里夺走了超过25万条生命,并引发了全球卫生紧急状况。科学界正在不懈努力设计和测试针对这种新型冠状病毒的疫苗和抗病毒药物,其中几种已进入高级测试阶段并正在进行临床试验。在此,我们讨论在理解COVID-19大流行的病因和流行病学、影响疾病传播的因素以及为抗击和阻止该疾病进一步传播而采取的对策方面的最新进展和动态。

相似文献

1
Opportunities, Challenges and Directions in Science and Technology for Tackling COVID-19.
Trans Indian Natl Acad Eng. 2020;5(2):97-101. doi: 10.1007/s41403-020-00111-z. Epub 2020 May 26.
3
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
4
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
7
SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.
Ann Clin Microbiol Antimicrob. 2020 Sep 2;19(1):40. doi: 10.1186/s12941-020-00384-w.
8
Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19.
Front Immunol. 2022 Apr 5;13:834942. doi: 10.3389/fimmu.2022.834942. eCollection 2022.
9
SARS-CoV-2/COVID-19: a primer for cardiologists.
Neth Heart J. 2020 Jul;28(7-8):366-383. doi: 10.1007/s12471-020-01475-1.

引用本文的文献

1
Linkages between environmental issues and zoonotic diseases: with reference to COVID-19 pandemic.
Environ Sustain (Singap). 2021;4(3):455-467. doi: 10.1007/s42398-021-00165-x. Epub 2021 Mar 29.
2
PREFACE on the Special Issue 'Technologies for Fighting COVID-19'.
Trans Indian Natl Acad Eng. 2020;5(2):91-95. doi: 10.1007/s41403-020-00156-0. Epub 2020 Jul 25.

本文引用的文献

1
Current status of potential therapeutic candidates for the COVID-19 crisis.
Brain Behav Immun. 2020 Jul;87:59-73. doi: 10.1016/j.bbi.2020.04.046. Epub 2020 Apr 22.
2
Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period.
Science. 2020 May 22;368(6493):860-868. doi: 10.1126/science.abb5793. Epub 2020 Apr 14.
3
Phylogenetic network analysis of SARS-CoV-2 genomes.
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9241-9243. doi: 10.1073/pnas.2004999117. Epub 2020 Apr 8.
4
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.
5
Coronavirus disease 2019 (COVID-19): a clinical update.
Front Med. 2020 Apr;14(2):126-135. doi: 10.1007/s11684-020-0767-8. Epub 2020 Apr 2.
6
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.
Science. 2020 Apr 24;368(6489):409-412. doi: 10.1126/science.abb3405. Epub 2020 Mar 20.
8
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
9
A new coronavirus associated with human respiratory disease in China.
Nature. 2020 Mar;579(7798):265-269. doi: 10.1038/s41586-020-2008-3. Epub 2020 Feb 3.
10
A pneumonia outbreak associated with a new coronavirus of probable bat origin.
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验